Related references
Note: Only part of the references are listed.Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan
Julia E. McGuinness et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2021)
Repurposing elesclomol, an investigational drug for the treatment of copper metabolism disorders
Vishal M. Gohil
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)
Unlocking the potential of antibody-drug conjugates for cancer therapy
Joshua Z. Drago et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive
Dey Nandini et al.
PHARMACEUTICALS (2021)
Weekly ladiratuzumab vedotin monotherapy for metastatic triple-negative breast cancer
M. Tsai et al.
ANNALS OF ONCOLOGY (2021)
Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions
Emanuela Ferraro et al.
BREAST CANCER RESEARCH (2021)
Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer
Elia Cipriano et al.
BREAST CANCER-BASIC AND CLINICAL RESEARCH (2021)
Metformin and cancer immunity
Ruixia Ma et al.
ACTA PHARMACOLOGICA SINICA (2020)
Role of the gut microbiome for cancer patients receiving immunotherapy: Dietary and treatment implications
Karla A. Lee et al.
EUROPEAN JOURNAL OF CANCER (2020)
Triple-negative breast cancer molecular subtyping and treatment progress
Li Yin et al.
BREAST CANCER RESEARCH (2020)
Novel antibody-drug conjugates for triple negative breast cancer
Aiko Nagayama et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review
Noam Ponde et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2019)
Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy?
Mark L. Zangardi et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)
Additional mechanisms of action of ladiratuzumab vedotin contribute to increased immune cell activation within the tumor
Anthony T. Cao et al.
CANCER RESEARCH (2018)
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Hashem O. Alsaab et al.
FRONTIERS IN PHARMACOLOGY (2017)
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Giampaolo Bianchini et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Cancer immunotherapy: harnessing the immune system to battle cancer
Yiping Yang
JOURNAL OF CLINICAL INVESTIGATION (2015)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)